Insider filing · ELVN
Benjamin Hohl
CHIEF FINANCIAL OFFICER
profile →
Enliven Therapeutics, Inc.
ELVN · Healthcare · 61 filings in 24 months
ticker →
Benjamin Hohl sold $275K of Enliven Therapeutics (ELVN)
Executed Jul 17, disclosed Jul 21, 4 days later.
Value, as filed
$275K
5,202 sh across 2 lots
Executed
Jul 17
the trade date, as filed
Disclosed
Jul 21
4 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
BHBenjamin Hohl (CHIEF FINANCIAL OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $296K of ELVN (10,000 sh × $29.58, as filed), executed Mar 6.
The name
ELVNHealthcare · Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibito…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Benjamin Hohl in ELVN
ELVNSALE
Enliven Therapeutics, Inc.
$288K5,729 sh across 2 lots
Exec Sep 17
Filed Sep 21 · 5:23 PM ET ELVNSALE Enliven Therapeutics, Inc. $270K
4,630 sh × $58.35
Exec Aug 17
Filed Aug 19 · 4:17 PM ET ELVNSALE Enliven Therapeutics, Inc. $149K
3,401 sh × $43.86
Exec Jun 17
Filed Jun 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $296K
10,000 sh × $29.58
Exec Mar 6
Filed Mar 10 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $105K
4,250 sh × $24.78
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $160K
5,600 sh × $28.49
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $281K
10,218 sh × $27.51
Exec Oct 4 2024
Filed Oct 8 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $103K
4,250 sh × $24.27
Exec Sep 27 2024
Filed Oct 1 2024 · 5:30 PM ET